In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017–2020
Yu-Lin Lee,Wen-Chien Ko,Wen-Sen Lee,Po-Liang Lu,Yen-Hsu Chen,Shu-Hsing Cheng,Min-Chi Lu,Chi-Ying Lin,Ting-Shu Wu,Muh-Yong Yen,Lih-Shinn Wang,Chang-Pan Liu,Pei-Lan Shao,Zhi-Yuan Shi,Yao-Shen Chen,Fu-Der Wang,Shu-Hui Tseng,Chao-Nan Lin,Yu-Hui Chen,Wang-Huei Sheng,Chun-Ming Lee,Hung-Jen Tang,Po-Ren Hsueh
DOI: https://doi.org/10.1016/j.ijantimicag.2021.106377
IF: 15.441
2021-09-01
International Journal of Antimicrobial Agents
Abstract:<p>In this study, the susceptibility of carbapenem-nonsusceptible Enterobacterales (CNSE) to cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline, and other comparative agents was examined. Non-duplicate Enterobacterales isolates from 16 Taiwanese hospitals were evaluated. Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method, and susceptibility results were interpreted based on relevant guidelines. A total of 201 CNSE isolates were investigated, including 26 <em>Escherichia coli</em> and 175 <em>Klebsiella pneumoniae</em> isolates. Carbapenemase genes were detected in 15.4% (<em>n</em> = 4) of <em>E. coli</em> and 47.4% (<em>n</em> = 83) of <em>K. pneumoniae</em> isolates, with the most common being <em>bla</em><sub>KPC</sub> (79.3%, 69/87), followed by <em>bla</em><sub>OXA-48-like</sub> (13.8%, 12/87). Cefiderocol was the most active agent against CNSE; only 3.8% (<em>n</em> = 1) of <em>E. coli</em> and 4.6% (<em>n</em> = 8) of <em>K. pneumoniae</em> isolates were not susceptible to this agent. Among the CR-<em>E. coli</em> and <em>K. pneumoniae</em> isolates, 88.5% (<em>n</em> = 23) and 93.7% (<em>n</em> = 164), respectively, were susceptible to ceftazidime/avibactam. For cefepime/zidebactarm, 23 (88.5%) <em>E. coli</em> and 155 (88.6) <em>K. pneumoniae</em> isolates had MICs of–≤2/2 mg/L. For cefepime/enmetazobactam, 22 (84.6%) <em>E. coli</em> and 85 (48.6%) <em>K. pneumonia</em>e isolates had MICs of–≤2/8 mg/L. The higher MICs of <em>K. pneumonia</em>e against cefepime/enmetazobactam were due to only one (1.5%) of the 67 <em>bla</em><sub>KPC</sub>-carrying isolates being susceptible. The MICs of omadacycline were significantly higher than those of eravacycline and tigecycline. In summary, cefiderocol, ceftazidime/avibactam, and cefepime/zidebactam were more effective against CNS <em>E. coli</em> and <em>K. pneumoniae</em>, than other drugs; highlighting their potential as valuable therapeutics.</p>
pharmacology & pharmacy,infectious diseases,microbiology